Liquidation: ETF Series Solutions

Form Type: 497

Filing Date: 2025-05-07

Corporate Action: Liquidation

Type: New

Accession Number: 000089418925003672

Filing Summary: The Board of Trustees of ETF Series Solutions has decided to liquidate the Range Cancer Therapeutics ETF, effective immediately after the close of business on May 27, 2025. Effective May 13, 2025, the Fund will begin liquidating its portfolio assets, leading to an increase in cash holdings and a deviation from the stated investment objectives. New creation units shall not be accepted after the close of business on the business day before the Liquidation Date, with trading halted prior to market open on that date. Shareholders may only sell shares to specific broker-dealers with no guarantee of a market for shares. On the Liquidation Date, the Fund will liquidate its assets and distribute cash pro rata to remaining shareholders, which will be taxable events. Shareholders are advised to consult tax advisors regarding the implications. The Fund will terminate once the distributions are complete, and proceeds will be sent to shareholders promptly after the Liquidation Date.

Document Link: View Document

Form Type: 497

Filing Date: 2025-04-14

Corporate Action: Liquidation

Type: New

Accession Number: 000089418925002426

Filing Summary: The Board of Trustees of ETF Series Solutions, upon a recommendation from Defiance ETFs, LLC, has determined to close and liquidate the Defiance Next Gen H2 ETF (HDRO) immediately after the close of business on April 29, 2025. Effective on or about April 18, 2025, the Fund will begin liquidating its portfolio assets, leading to increased cash holdings that deviate from its investment objectives. The Fund will not accept new creation unit orders after the business day prior to the Liquidation Date. Trading in shares will be halted prior to market open on the Liquidation Date. Shareholders may sell shares only to certain broker-dealers, with no assurance of a market for the shares. Upon Liquidation Date, the Fund will liquidate assets and distribute cash pro rata to remaining shareholders, with these distributions being taxable events. Shareholders are advised to consult their tax advisor regarding the tax implications. Following distributions, the Fund will terminate, and liquidation proceeds will be sent to shareholders promptly thereafter. Shareholders are encouraged to retain this Supplement with their Summary Prospectus, Prospectus, and SAI for future reference.

Document Link: View Document

Form Type: 497

Filing Date: 2025-04-14

Corporate Action: Liquidation

Type: New

Accession Number: 000089418925002427

Filing Summary: The Board of Trustees of ETF Series Solutions has decided to liquidate the Defiance Hotel, Airline, and Cruise ETF (CRUZ), effective immediately after the close of business on April 29, 2025. This decision follows a recommendation from the investment adviser, Defiance ETFs, LLC. The liquidation process will commence on or about April 18, 2025, with the Fund liquidating its portfolio assets, which will lead to increased cash holdings and a deviation from the Fund's stated investment objectives. No new creation units will be accepted after the close of business on the business day prior to the Liquidation Date, and trading in the Fund's shares will cease before the market opens on that date. Shareholders may face restrictions when selling their shares prior to the Liquidation Date. On the Liquidation Date, cash distributions will be made to all remaining shareholders based on the liquidation of the Fund’s assets, which constitutes a taxable event. Shareholders are advised to consult their tax advisors regarding the potential tax implications of the liquidation. After all distributions, the Fund will terminate, and proceeds will be sent to shareholders after the Liquidation Date. Shareholders are encouraged to retain this Supplement with their Summary Prospectus, Prospectus, and Statement of Additional Information for future reference.

Document Link: View Document